ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$19.98 USD
+0.24 (1.22%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.09 +0.11 (0.55%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Cash flow Statements
Fiscal Year End for ADMA Biologics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -28.24 | -65.90 | -71.65 | -75.75 | -48.28 |
Depreciation/Amortization & Depletion | 10.78 | 9.37 | 7.25 | 5.58 | 4.30 |
Net Change from Assets/Liabilities | -10.12 | -18.29 | -51.68 | -33.78 | -33.50 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 36.38 | 15.31 | 3.71 | 1.95 | 1.29 |
Net Cash From Operating Activities | 8.80 | -59.51 | -112.37 | -102.00 | -76.19 |
Property & Equipment | -4.77 | -13.91 | -13.51 | -12.72 | -3.81 |
Acquisition/ Disposition of Subsidiaries | -0.21 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -4.98 | -13.91 | -13.51 | -12.72 | -3.81 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.10 | 64.82 | 121.14 | 131.21 | 48.47 |
Issuance (Repayment) of Debt | -36.33 | 49.71 | -0.03 | 12.69 | 33.21 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -3.77 | -5.68 | -0.06 | 0.00 | -1.68 |
Net Cash from Financing Activities | -38.99 | 108.85 | 121.05 | 143.90 | 80.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -35.17 | 35.43 | -4.83 | 29.17 | 0.00 |
Cash at Beginning of Period | 86.52 | 51.09 | 55.92 | 26.75 | 26.75 |
Cash at End of Period | 51.35 | 86.52 | 51.09 | 55.92 | 26.75 |
Diluted Net EPS | -0.13 | -0.33 | -0.51 | -0.88 | -0.89 |
Fiscal Year End for ADMA Biologics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 49.87 | 17.81 | -28.24 | -10.59 | -13.16 |
Depreciation/Amortization & Depletion | 4.57 | 2.33 | 10.78 | 8.01 | 5.23 |
Net Change from Assets/Liabilities | -16.04 | -24.52 | -10.12 | -13.72 | -17.59 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.03 | 2.16 | 36.38 | 7.51 | 4.73 |
Net Cash From Operating Activities | 43.43 | -2.22 | 8.80 | -8.80 | -20.78 |
Property & Equipment | -4.41 | -2.35 | -4.77 | -3.57 | -2.82 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -0.02 | -0.21 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -0.31 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -4.73 | -2.36 | -4.98 | -3.57 | -2.82 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.36 | 1.03 | 1.10 | 1.10 | 0.47 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -36.33 | -0.02 | -0.02 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -3.17 | -2.48 | -3.77 | -1.07 | -0.87 |
Net Cash from Financing Activities | -1.81 | -1.45 | -38.99 | 0.00 | -0.41 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 36.89 | -6.03 | -35.17 | -12.36 | -24.01 |
Cash at Beginning of Period | 51.35 | 51.35 | 86.52 | 86.52 | 86.52 |
Cash at End of Period | 88.24 | 45.33 | 51.35 | 74.16 | 62.51 |
Diluted Net EPS | 0.13 | 0.08 | -0.08 | 0.01 | -0.03 |